PMID- 22404300
OWN - NLM
STAT- MEDLINE
DCOM- 20121030
LR  - 20211021
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 166
IP  - 5
DP  - 2012 Jul
TI  - MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in 
      humans - no need for translation.
PG  - 1518-20; discussion 1521-2
LID - 10.1111/j.1476-5381.2012.01941.x [doi]
AB  - In this issue of the BJP, Green et al. suggest that animal data could not be used 
      to predict the adverse effects of 3,4-methylenedioxymethamphetamine (MDMA) in 
      humans and that MDMA did not produce 5-HT neurotoxicity in the human brain. This 
      proposal was, however, not accompanied by a review of the empirical evidence in 
      humans. The neuroimaging data on 5-HT markers in abstinent recreational 
      ecstasy/MDMA users are extensive and broadly consistent. Reduced levels of the 
      5-HT transporter (SERT) have been found by research groups worldwide using a 
      variety of assessment measures. These SERT reductions occur across the higher 
      brain regions and remain after controlling for potential confounds. There are 
      also extensive empirical data for impairments in memory and higher cognition, 
      with the neurocognitive deficits correlating with the extent of SERT loss. Hence, 
      MDMA is clearly damaging to humans, with extensive empirical data for both 
      structural and functional deficits.
CI  - (c) 2012 The Author. British Journal of Pharmacology (c) 2012 The British 
      Pharmacological Society.
FAU - Parrott, Andrew C
AU  - Parrott AC
AD  - Department of Psychology, Swansea University, UK. a.c.parrott@swansea.ac.uk
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
CON - Br J Pharmacol. 2012 Jul;166(5):1523-36. PMID: 22188379
MH  - Animals
MH  - Hallucinogens/*adverse effects
MH  - Humans
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects
MH  - Neurotoxicity Syndromes/*etiology
PMC - PMC3419896
EDAT- 2012/03/13 06:00
MHDA- 2012/10/31 06:00
PMCR- 2013/07/01
CRDT- 2012/03/13 06:00
PHST- 2012/03/13 06:00 [entrez]
PHST- 2012/03/13 06:00 [pubmed]
PHST- 2012/10/31 06:00 [medline]
PHST- 2013/07/01 00:00 [pmc-release]
AID - 10.1111/j.1476-5381.2012.01941.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 2012 Jul;166(5):1518-20; discussion 1521-2. doi: 
      10.1111/j.1476-5381.2012.01941.x.